N@N

Rosetta Genomics to Present at Leerink Swana?s Life Science Tools and Diagnostics Roundtable Conference

^{Published on 2010-07-30 05:10:59 - Market Wire}
 

PHILADELPHIA & REHOVOT, Israel--([ BUSINESS WIRE ])--Rosetta Genomics, Ltd. (NASDAQ:ROSG) a leading developer of microRNA-based molecular diagnostics, announced that Kenneth A. Berlin, president and chief executive officer, will be participating in a panel discussion entitled, aIssues and Opportunities in Molecular Diagnostics,a at 11:00 a.m. and will be presenting a corporate update at 1:10 p.m. at Leerink Swana™s Life Science Tools and Diagnostics Roundtable Conference being held on Thursday, August 5, 2010 at The Roosevelt Hotel in New York City.

Leerink Swana™s Roundtable Conference is a one-day meeting consisting of a series of moderated discussions with panels of MEDACorp research, clinical specialists, key members of management (CEOs, CFOs and CMOs) from the companies attending the conference, as well as institutional investors who specialize in the healthcare sector. In addition, several companies will be presenting corporate overviews.

Mr. Berlin will be available for one-on-one meetings with investors participating in the Leerink Swan Roundtable Conference. For those who would like to schedule an appointment with Rosetta Genomicsa™ management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at [ afields@lhai.com ] or contact your Leerink Swan representative.

About Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000, the companya™s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The companya™s first three microRNA-based tests, miRviewa" squamous, miRviewa" mets and miRviewa" meso, are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit [ www.rosettagenomics.com ].

Forward-Looking Statements

Various statements in this release concerning Rosettaa™s future expectations, plans and prospects, including without limitation, statements relating to thedevelopment of early detection cancer screening products,including anon-invasive colon cancer screening test, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under aKey Information - Risk Factorsa in Rosettaa™s Annual Report on Form 20-F for the year ended December 31, 2009 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosettaa™s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.